LillyDirect is Eli Lilly selling to you instead of through the usual chain of wholesaler, pharmacy benefit manager and retail counter. Your prescriber routes the prescription to LillyDirect Pharmacy, a third-party fulfillment pharmacy fills it, and you either get free home delivery or pick it up at a participating retail location. The point of the channel is a published cash price that does not move based on which plan you have.
That published price is the whole story, and it is not one number. It ranges from $35 a month for insulin to $699 a month for a high Zepbound dose refilled late. This guide covers what each medicine on the LillyDirect catalog costs self-pay as of September 2026, the refill rule that can more than double the Zepbound price, why insurance generally cannot be used for these prices, and how the cash price compares to Lilly’s own list price and to pharmacy acquisition cost.
What Does LillyDirect Cost Without Insurance?
Every figure below comes from Lilly’s own product pages, checked September 6, 2026. A “month” is defined differently by product, which matters: Zepbound is 28 days, Foundayo and the insulins are 30 days.
| Medicine (self-pay, per month) | Low | Typical | High |
|---|---|---|---|
| Zepbound single-dose vial or KwikPen | $299 (2.5 mg) | $449 (7.5-15 mg, on schedule) | $699 (10-15 mg, late refill) |
| Mounjaro single-dose prefilled pen | $499 | $499 | $499 |
| Foundayo (orforglipron) tablets | $149 (0.8-2.5 mg) | $199 (5.5 mg) | $299 (9-17.2 mg) |
| Trulicity single-dose pen | $389 | $389 | $389 |
| Emgality (100 or 120 mg/mL) | $299 | $299 | $299 |
| Humalog, Humulin, Basaglar, Rezvoglar, Lyumjev | $35 | $35 | $35 |
| Zepbound list price, for comparison | $499 | n/a | $1,086.37 |
Zepbound. Lilly prices the single-dose vial and the single-patient-use KwikPen identically: $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg, 10 mg, 12.5 mg and 15 mg. The $449 figure on the top four doses is the Zepbound Self Pay Journey Program price and it is conditional. Lilly’s savings terms state the regular one-month self-pay price is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for 10 mg, 12.5 mg and 15 mg. The vial is labeled self-pay only and sold exclusively through LillyDirect. Our Zepbound cost guide and Zepbound vials cost guide break the per-dose math down further.
Mounjaro. Every strength of the single-dose prefilled pen is $499 a month self-pay, with taxes and fees noted as possible additions. That is a flat price across 2.5 mg through 15 mg, which makes Mounjaro the more expensive tirzepatide at low doses and the cheaper one if you would otherwise be paying a late-refill Zepbound price. See Mounjaro cost without insurance.
Foundayo. Lilly’s oral GLP-1 (orforglipron) is $149 a month at 0.8 mg and 2.5 mg, $199 at 5.5 mg, and $299 at 9 mg, 14.5 mg and 17.2 mg. Two footnotes matter. The 2.5 mg and 5.5 mg prices are flagged as temporarily reduced through December 31, 2026, and the 14.5 mg and 17.2 mg prices depend on a 45-day refill window the same way Zepbound does.
Insulin. Any Lilly insulin is $35 for a 30-day supply through the Lilly Insulin Value Program, whether you have commercial insurance or none at all. That covers the Humalog family, the Humulin family, Basaglar, Rezvoglar and Lyumjev. Lilly’s own page notes the card expires December 31, 2026 and that people in federal programs are excluded, though federal law separately caps Part D insulin at $35 a month. More context in our insulin cost guide.
Emgality. $299 a month self-pay, or $35 a month if you are commercially insured with coverage. A month here is 30 days and up to two pens or three syringes. Details in the Emgality cost guide.
What Drives the Price
The 45-day refill clock. This is the single biggest swing on the platform. On Zepbound 7.5 mg and up, refilling within 45 days of your previous delivery holds the price at $449. Refill later and you pay $499 or $699 depending on dose, a swing of up to $250 a month. Foundayo’s top two doses work the same way. Nothing about the drug changes, only the timing.
Which device your prescription names. The Zepbound single-dose pen is not part of the self-pay ladder at all. It is the insurance product, priced at as little as $25 a month with a commercial plan that covers it. The vial and the KwikPen are the cash products. A prescription written for the wrong device gets you the wrong price.
Supplies that are not in the box. The vial needs a needle and syringe you buy separately. The KwikPen needs pen needles. The single-dose pen includes its needle. Budget a few dollars a month either way, but confirm before you assume the quoted price is all-in.
Promotional windows. Foundayo’s low and middle doses carry a stated end date of December 31, 2026. Lilly’s savings card terms also end December 31, 2026. Direct-to-patient GLP-1 pricing has moved several times in the last year, so treat any figure here as a September 2026 snapshot and re-check at checkout.
Telehealth and shipping. Delivery is free. If you need a prescriber, LillyDirect links to independent third-party telehealth partners whose own fees range from about $29 a visit to $149 a month for self-pay memberships, and roughly $25 to $31 a visit if the partner bills your insurance. Those fees are the partner’s, not Lilly’s, and they sit on top of the drug price.
Cash Price vs. Insurance
The core trade-off is simple. LillyDirect self-pay is often cheaper than a plan’s cost share for a non-preferred GLP-1, but the money is invisible to your plan.
Nothing you pay in the self-pay channel counts toward a commercial deductible, an out-of-pocket maximum, or the Medicare Part D cap. Medicare.gov puts the 2026 Part D annual out-of-pocket cap at $2,100, with plan deductibles capped at $615. If you are a Part D member with real coverage for the drug, paying $449 in cash twelve times gets you $5,388 of spending that moves you zero dollars closer to that $2,100 ceiling. See our Medicare Part D guide for how the cap actually works.
Lilly’s commercial savings cards exclude government beneficiaries outright: Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE and state drug assistance programs. The workaround Lilly built is the Medicare GLP-1 Bridge, which prices Foundayo and the Zepbound single-patient-use KwikPen at no more than $50 a month for eligible Part D members. Eligibility requires being 18 or older, having Part D drug coverage, a prescription for chronic weight management rather than diabetes or sleep apnea, and a BMI of 35 or higher (or 27 or higher with a weight-related condition). It runs through prior authorization and is billed as primary insurance, and Lilly is explicit that it is not a guarantee of coverage. The Zepbound single-dose pen and single-dose vial are excluded.
Against list price, the cash channel looks strong. Lilly’s own pricing-disclosure site puts the Zepbound list price at $499 to $1,086.37 per fill depending on format. CMS National Average Drug Acquisition Cost data effective August 19, 2026 shows pharmacies acquiring the Zepbound single-dose pen at about $525.78 per mL, roughly $1,052 for a four-pen 28-day supply, and Mounjaro at about $538.60 per mL, roughly $1,077 a month. A $449 or $499 cash price sits well under what a retail pharmacy pays for the pen, which is why discount cards have little room to beat it on these specific brands.
How to Pay Less
Price the same molecule at the other manufacturer’s channel. Semaglutide and tirzepatide are different drugs but often interchangeable in a coverage conversation. Novo’s competing channel prices Wegovy and Ozempic separately, and the gap moves. Compare against our NovoCare Pharmacy cost guide and the broader cheapest GLP-1 rundown before you settle.
Protect the 45-day window. Set a reminder for day 30 after each delivery. On Zepbound 10 mg and up this one habit is worth $250 a month, or $3,000 a year. Our cheapest way to get Zepbound guide covers the ordering mechanics in detail.
Ask specifically about the Medicare GLP-1 Bridge if you have Part D. It is not advertised at the pharmacy counter and it requires the KwikPen, not the vial or the single-dose pen. At $50 a month it is the cheapest legitimate route for a Part D member who meets the clinical criteria.
Use HSA or FSA dollars. Lilly flags the GLP-1 products as HSA and FSA eligible, subject to your plan. Paying a $449 cash price with pre-tax money is effectively a 20 to 35 percent discount depending on your bracket.
Check whether you qualify for free medicine instead. Lilly Cares and similar manufacturer programs supply some drugs at no cost to patients under income limits, which beats any cash price. Start with prescription assistance programs.
Verify the number against a second source. Direct-to-patient prices have changed repeatedly since late 2025, and Lilly’s press releases and product pages have carried different late-refill figures at the same time. Run your dose through our fair price checker and confirm the final number in the LillyDirect checkout before you pay.
The Bottom Line
LillyDirect is a real discount for people without drug coverage: $299 to $449 a month for Zepbound against a $1,086 list price, $499 for Mounjaro against roughly $1,077 in pharmacy acquisition cost, and $35 for insulin. It is a worse deal for anyone whose plan already covers the drug at a lower cost share, and a genuinely bad deal for a Part D member who could otherwise be spending toward the $2,100 cap.
Two rules cover most of it. Refill on time, and confirm which device your prescription names. Those two details account for nearly every dollar of variation in what LillyDirect actually charges. Broader pricing policy is shifting too, and our guide to most favored nation drug pricing covers where these direct-to-patient prices came from.